Rhabdomyolysis due to bezafibrate in CAPD patients. A role for dihydropyridine drugs?
Weissgarten
J
J
Department of Nephrology, Assaf Harofeh Medical Center, Zerifin, Israel.
Zaidenstein
R
R
Fishman
S
S
Dishi
V
V
Michovitz-Koren
M
M
Averbukh
Z
Z
Golik
A
A
D000328:Adult; D000368:Aged; D001629:Bezafibrate / Q000009:adverse effects* / Q000627:therapeutic use; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004095:Dihydropyridines / Q000494:pharmacology*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D006899:Mixed Function Oxygenases / Q000378:metabolism; D010531:Peritoneal Dialysis, Continuous Ambulatory; D012206:Rhabdomyolysis / Q000139:chemically induced*
D004095:Dihydropyridines; D000960:Hypolipidemic Agents; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D001629:Bezafibrate